Agentix Corp.

OTC:AGTX

Biological Products, (No Diagnostic Substances)·DANA POINT, CA

Summary Financials

Revenue

$1,240

FY 2023

Adj. EBITDA

-$744,546

-60044.0% margin

FY 2025

Net Income

-$585,154

-47189.8% margin

FY 2025

EPS (Diluted)

-$0.01

FY 2025

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$145

FY 2023

Total Debt

$25,000

FY 2019

Net Debt

$24,855

FY 2019

Enterprise Value

—

Debt / EBITDA

-0.0x

FY 2023

EV / EBITDA

—

Employees

—

Revenue

$1,240

FY 2023

Adj. EBITDA

-$744,546

-60044.0% margin

FY 2025

Net Income

-$585,154

-47189.8% margin

FY 2025

EPS (Diluted)

-$0.01

FY 2025

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$145

FY 2023

Total Debt

$25,000

FY 2019

Net Debt

$24,855

FY 2019

Enterprise Value

—

Debt / EBITDA

-0.0x

FY 2023

EV / EBITDA

—

Employees

—